Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visudyne + Lucentis for age-related macular degeneration
ACTRN12609001051235Phase 4Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- Sep 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of verteporfin and ranibizumab in age-related macular degeneration (AMD), sponsored by Royal Adelaide Hospital. Primary endpoint: Mean change from baseline in best corrected visual acuity. Started Sep 2007; status: recruiting.
02
Drugs
verteporfinranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ACTRN12609001051235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609001051235.